Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
McKesson
Medtronic
McKinsey
Dow

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for PF-04991532

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug PF-04991532?

PF-04991532 is an investigational drug.

There have been 9 clinical trials for PF-04991532. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2011.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Metabolic Diseases. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are four US patents protecting this investigational drug and fifty international patents.

Recent Clinical Trials for PF-04991532
TitleSponsorPhase
A 2-week Trial Of PF-04991532 In Patients With Type 2 DiabetesPfizerPhase 1
Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532PfizerPhase 1
Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532PfizerPhase 1

See all PF-04991532 clinical trials

Clinical Trial Summary for PF-04991532

Top disease conditions for PF-04991532
Top clinical trial sponsors for PF-04991532

See all PF-04991532 clinical trials

US Patents for PF-04991532

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-04991532   Start Trial Substituted imidazole propanamide glucokinase activators Pfizer Inc (New York, NY)   Start Trial
PF-04991532   Start Trial Substituted imidazoles useful for treating type II diabetes Pfizer Inc. (New York, NY)   Start Trial
PF-04991532   Start Trial (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamid- o)nicotinic acid useful as a glucokinase activator Pfizer Inc. (New York, NY)   Start Trial
PF-04991532   Start Trial Phenylacetamide compound and pharmaceutical containing same Kowa Company, Ltd. (Aichi, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-04991532

Drugname Country Document Number Estimated Expiration Related US Patent
PF-04991532 Argentina 073283 2028-09-11   Start Trial
PF-04991532 Australia 2009290474 2028-09-11   Start Trial
PF-04991532 Brazil PI0918128 2028-09-11   Start Trial
PF-04991532 Canada 2735184 2028-09-11   Start Trial
PF-04991532 Chile 2011000478 2028-09-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Express Scripts
Dow
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.